Study links cadmium exposure to elevated osteoarthritis risk via cellular senescence and FOXO pathways

An integrative analysis of NHANES epidemiological data and network toxicology suggests that elevated blood cadmium levels are significantly associated with osteoarthritis risk, driven by cellular senescence and FOXO signaling pathways.

Researchers integrated epidemiological data from the 2013-2018 National Health and Nutrition Examination Survey (NHANES) with computational toxicology to evaluate the correlation between cadmium exposure and osteoarthritis.

Multivariate logistic regression models showed that elevated blood cadmium levels were significantly associated with an increased risk of osteoarthritis, with more pronounced associations in patients with diabetes, hypertension, vitamin D deficiency, low income, and smokers.

By combining differentially expressed genes in osteoarthritis, weighted gene co-expression network analysis (WGCNA), and protein-protein interaction networks, the study identified 113 intersection genes.

Gene Ontology and KEGG pathway enrichment analyses suggested that cadmium contributes to osteoarthritis progression by regulating cellular senescence, FOXO signaling, and TNF signaling pathways.

Six key hub genes—MYC, FOXO1, FOXO3, ZFP36, AIF1, and KLF4—were identified, and molecular docking simulations validated their strong binding affinity with cadmium nitrate.

The study establishes a systematic epidemiological and molecular network connecting a common environmental toxicant to the pathogenesis of osteoarthritis, a prevalent age-related disease.

The work highlights cellular senescence and FOXO signaling—both widely studied targets in longevity biotechnology—as central mechanisms of cadmium-induced joint damage.

The data suggest that lifestyle factors such as smoking and nutritional deficiencies like low vitamin D can synergize with environmental exposures to worsen degenerative joint pathology.

These mechanistic insights support the therapeutic relevance of targeting cellular senescence and FOXO signaling pathways to prevent or halt osteoarthritis progression.

The findings imply that environmental toxicant exposure, particularly cadmium levels, may act as a confounding variable in clinical trials for osteoarthritis therapies, suggesting a role for patient stratification.

Preclinical studies evaluating whether senolytic drugs or FOXO pathway activators can prevent or reverse cadmium-induced joint degradation.